| Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer GE Konecny, C Wang, H Hamidi, B Winterhoff, KR Kalli, J Dering, ... Journal of the National Cancer Institute 106 (10), dju249, 2014 | 374 | 2014 |
| Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade RJ Motzer, R Banchereau, H Hamidi, T Powles, D McDermott, MB Atkins, ... Cancer cell 38 (6), 803-817. e4, 2020 | 334 | 2020 |
| MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors J Jaboin, J Wild, H Hamidi, C Khanna, CJ Kim, R Robey, SE Bates, ... Cancer research 62 (21), 6108-6115, 2002 | 305 | 2002 |
| Clinical Characteristics of Ovarian Cancer Classified by BRCA1, BRCA2 and RAD51C Status JM Cunningham, MS Cicek, NB Larson, J Davila, C Wang, MC Larson, ... Scientific reports 4 (1), 4026, 2014 | 158 | 2014 |
| PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and … JE Logan, N Mostofizadeh, AJ Desai, E Von Euw, D Conklin, V Konkankit, ... Anticancer research 33 (8), 2997-3004, 2013 | 113 | 2013 |
| Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated … RJ Motzer, T Powles, MB Atkins, B Escudier, DF McDermott, BY Alekseev, ... JAMA oncology 8 (2), 275-280, 2022 | 102 | 2022 |
| Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel MS Cicek, DC Koestler, BL Fridley, KR Kalli, SM Armasu, MC Larson, ... Human molecular genetics 22 (15), 3038-3047, 2013 | 101 | 2013 |
| The HSP90 inhibitor NVP-AUY922 potently inhibits non–small cell lung cancer growth EB Garon, RS Finn, H Hamidi, J Dering, S Pitts, N Kamranpour, AJ Desai, ... Molecular cancer therapeutics 12 (6), 890-900, 2013 | 87 | 2013 |
| Estrogen receptor (ER) α-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression BG Drew, H Hamidi, Z Zhou, CJ Villanueva, SA Krum, AC Calkin, ... Journal of Biological Chemistry 290 (9), 5566-5581, 2015 | 76 | 2015 |
| Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures B Winterhoff, H Hamidi, C Wang, KR Kalli, BL Fridley, J Dering, HW Chen, ... Gynecologic oncology 141 (1), 95-100, 2016 | 65 | 2016 |
| A multimodal and integrated approach to interrogate human kidney biopsies with rigor and reproducibility: guidelines from the Kidney Precision Medicine Project TM El-Achkar, MT Eadon, R Menon, BB Lake, TK Sigdel, T Alexandrov, ... Physiological genomics 53 (1), 1-11, 2021 | 58 | 2021 |
| Identification of novel targets of CSL-dependent Notch signaling in hematopoiesis H Hamidi, D Gustafason, M Pellegrini, J Gasson PloS one 6 (5), e20022, 2011 | 58 | 2011 |
| Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance Y He, AC Wu, BS Harrington, CM Davies, SJ Wallace, MN Adams, ... Oncogene 35 (4), 468-478, 2016 | 56 | 2016 |
| KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition DJSRSF H Hamidi1, M Lu1, K Chau1, L Anderson1, M Fejzo1, C Ginther1, R ... British Journal of Cancer, 2014 | 54 | 2014 |
| Functional analysis of the EWS/ETS target gene uridine phosphorylase B Deneen, H Hamidi, CT Denny Cancer Research 63 (14), 4268-4274, 2003 | 54 | 2003 |
| Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab F Ather, H Hamidi, MS Fejzo, S Letrent, RS Finn, F Kabbinavar, C Head, ... PloS one 8 (2), e56112, 2013 | 53 | 2013 |
| CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy MA Huseni, L Wang, JE Klementowicz, K Yuen, B Breart, C Orr, L Liu, Y Li, ... Cell Reports Medicine 4 (1), 2023 | 43 | 2023 |
| An integrative systems biology approach for precision medicine in diabetic kidney disease S Mulder, H Hamidi, M Kretzler, W Ju Diabetes, Obesity and Metabolism 20, 6-13, 2018 | 37 | 2018 |
| Comprehensive cross-population analysis of high-grade serous ovarian cancer supports no more than three subtypes GP Way, J Rudd, C Wang, H Hamidi, BL Fridley, GE Konecny, EL Goode, ... G3: Genes, Genomes, Genetics 6 (12), 4097-4103, 2016 | 36 | 2016 |
| Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo)+ platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC … MD Galsky, R Banchereau, HR Hamidi, N Leng, W Harris, PH O'Donnell, ... Journal of Clinical Oncology 38 (15_suppl), 5011-5011, 2020 | 30 | 2020 |
Chen WangMayo Clinic在 mayo.edu 的电子邮件经过验证
